Nasdaq · CIK 0001367083
SNOA Sonoma Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Jan 2, 2026.
Sonoma Pharmaceuticals, Inc. (SNOA) has 13 SEC Form 4 filings on file from 7 insiders, the latest filed on Jan 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 Form 144 notices of planned sales are on file, the latest filed Jan 3, 2025.
Last 90 days
Signals
Open-market buys and sells at Sonoma Pharmaceuticals, Inc., scored.
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 3, 2025 | Gottfurcht Grant 10% Stockholder | 86,111 6.43% of outstanding | $232k | Jan 3, 2025 | $129k |
| Jan 2, 2025 | Gottfurcht Grant Open Market Purchase | 17,806 1.33% of outstanding | $49k | Dec 31, 2024 | none |
| Jan 2, 2025 | Gottfurcht Grant Open Market | 30,000 2.24% of outstanding | $81k | Jan 2, 2025 | $54k |
| Dec 26, 2024 | Gottfurcht Grant 10% Stockholder | 221,375 7.41% of outstanding | $56k | Aug 9, 2024 | none |
Transactions
Every row filed, 13 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Jay E Birnbaum director | AGrant or award Stock option (right to buy)derivative | +10,000 | - | - | 20,001 | Jan 2, 2026 |
| Jan 2, 2026 | Jerome J Dvonch Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +5,000 | $0.00 | $0 | 34,391 | Jan 2, 2026 |
| Jan 2, 2026 | Poggetto John Dal Controller | AGrant or award Restricted Stock Unitsderivative | +5,000 | $0.00 | $0 | 25,250 | Jan 2, 2026 |
| Jan 2, 2026 | John McLaughlin director | AGrant or award Stock option (right to buy)derivative | +10,000 | - | - | 20,001 | Jan 2, 2026 |
| Jan 2, 2026 | Amy Moss Trombly Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +10,000 | $0.00 | $0 | 42,185 | Jan 2, 2026 |
| Jan 2, 2026 | Philippe Weigerstorfer director | AGrant or award Stock option (right to buy)derivative | +10,000 | - | - | 20,001 | Jan 2, 2026 |
| Jun 19, 2025 | Jerome J Dvonch Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +13,500 | $0.00 | $0 | 25,515 | Jun 20, 2025 |
| Jun 19, 2025 | Poggetto John Dal Controller | AGrant or award Restricted Stock Unitsderivative | +10,000 | $0.00 | $0 | 20,250 | Jun 20, 2025 |
| Jun 19, 2025 | Amy Moss Trombly Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +13,500 | $0.00 | $0 | 32,185 | Jun 20, 2025 |
| Jun 19, 2025 | Bruce Thornton Executive VP and COO | AGrant or award Restricted Stock Unitsderivative | +13,500 | $0.00 | $0 | 32,191 | Jun 20, 2025 |
| Jan 2, 2025 | Jay E Birnbaum director | AGrant or award Stock option (right to buy)derivative | +7,500 | - | - | 10,029 | Jan 3, 2025 |
| Jan 2, 2025 | Jerome J Dvonch Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +10,000 | $0.00 | $0 | 15,891 | Jan 3, 2025 |
| Jan 2, 2025 | Poggetto John Dal Controller | AGrant or award Restricted Stock Unitsderivative | +7,500 | $0.00 | $0 | 10,250 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jay E Birnbaumdirector
- Jerome J DvonchChief Financial Officer
- Poggetto John DalController
- John McLaughlindirector
- Bruce ThorntonExecutive VP and COO
- Amy Moss TromblyChief Executive Officer
- Philippe Weigerstorferdirector
Questions about SNOA
Answered from the filings on this page, as of the latest one.
Are insiders buying SNOA?
No. In the last 90 days no insider at Sonoma Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SNOA on the open market?
No open-market trade has been scored at Sonoma Pharmaceuticals, Inc.. The latest Form 4 on file was filed on Jan 2, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Sonoma Pharmaceuticals, Inc.?
7 people have filed a Form 4 at Sonoma Pharmaceuticals, Inc., among them Jay E Birnbaum (director), Jerome J Dvonch (Chief Financial Officer), Poggetto John Dal (Controller). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.